A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes.

ABSTRACT:

Background

Type 1 diabetes (T1D) is an autoimmune disease that leads to the progressive destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycemia. Current treatments focus on insulin replacement, but novel therapeutic approaches targeting β cell regeneration are needed. Dual-specificity tyrosine-phosphorylation-regulated kinases 1A (DYRK1A) and 1B (DYRK1B) play key roles in cell cycle regulation and β cell proliferation.

Methods

In this study, FX8474, a novel DYRK1 inhibitor, was evaluated in a streptozotocin (STZ)-induced diabetic mouse model. Mice were treated orally for 7 days, and pharmacokinetics, glucose regulation, and immune cell profiling were assessed.

Results

Pharmacokinetic analysis confirmed the oral bioavailability of FX8474, a

SUBMITTER: Tumas S 

PROVIDER: S-EPMC12555008 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature